Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Head and neck cancer; Male breast cancer; Oesophageal cancer; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-012
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 24 Mar 2023 Results developing the immuno-oncology Qsp platform model assessing efficacy prediction of Pembrolizumab + Enfortumab vedotin (EV) combination in phase II/III clinical trials from Keynote 12 and NCT032885452 studies, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 07 Jul 2020 Status changed from active, no longer recruiting to completed.
    • 31 May 2020 Results (N=132), assessing radiomic response in recurrent or metastatic head and neck squamous cell cancer patients receiving Pembrolizumab, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top